Biologic drugs

Question 1

mepolizumab

Answer 1

NUCALA. IL-5. Asthma, (eosinophilic esophagitis)

Question 2

reslizumab

Answer 2

CINQUAIR. IL-5. Asthma, (eosinophilic esophagitis)

Question 3

daclizumab

Answer 3

ZINBRYTA. CD25. MS (x), kidney transplant (?)

Question 4

ocrelizumab

Answer 4

OCREVUS. CD20. MS.

Question 5

rituximab

Answer 5

RITUXAN. Many cancers, esp. lymphoma. Many autoimmune diseases, esp. RA., (MS)

Question 6

infliximab

Answer 6

REMICADE {inflectra}. TNF-alpha. IBD, RA, psoriasis.

Question 7

natalizumab

Answer 7

TYSABRI. Alpha-4 integrin. MS, IBD.

Question 8

vedolizumab

Answer 8

ENTYVIO. Alpha-4 Beta-7 integrin. IBD.

Question 9

alemtuzumab

Answer 9

CAMPATH [cancer], LEMTRADA [MS]. CD52. CLL, lymphoma, MS.

Question 10

ustekinumab

Answer 10

STELARA. IL-12/IL-23. Psoriasis, IBD.

Question 11

omalizumab

Answer 11

XOLAIR. IgE. Asthma.

Question 12

benralizumab

Answer 12

FASENRA. CD125 (IL-5R). Eosinophilic asthma.

Question 13

abciximab

Answer 13

REOPRO. glycoprotein IIb/IIIa. Coronary artery procedure to prevent thrombus formation.

Question 14

secukinumab

Answer 14

COSENTYX. IL-17A. Psoriasis, ankylosing spondylitis, psoriatic arthritis.

Question 15

emecizumab

Answer 15

HEMLIBRA; activated factor IX and X (to activate factor X); substitute for factor XIII in hemophilia A

Question 16

bezlotoxumab

Answer 16

ZINPLAVA. C. diff toxin B. Prevention of C. diff in high-risk patients.